JATT vs. LXEO, KYTX, ADPT, CABA, ALEC, VYGR, TCRX, OCGN, EDIT, and ALLO
Should you be buying JATT Acquisition stock or one of its competitors? The main competitors of JATT Acquisition include Lexeo Therapeutics (LXEO), Kyverna Therapeutics (KYTX), Adaptive Biotechnologies (ADPT), Cabaletta Bio (CABA), Alector (ALEC), Voyager Therapeutics (VYGR), TScan Therapeutics (TCRX), Ocugen (OCGN), Editas Medicine (EDIT), and Allogene Therapeutics (ALLO). These companies are all part of the "biological products, except diagnostic" industry.
Lexeo Therapeutics (NASDAQ:LXEO) and JATT Acquisition (NYSE:JATT) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their media sentiment, valuation, community ranking, institutional ownership, earnings, profitability, risk, analyst recommendations and dividends.
In the previous week, Lexeo Therapeutics had 7 more articles in the media than JATT Acquisition. MarketBeat recorded 7 mentions for Lexeo Therapeutics and 0 mentions for JATT Acquisition. JATT Acquisition's average media sentiment score of 1.05 beat Lexeo Therapeutics' score of 0.00 indicating that Lexeo Therapeutics is being referred to more favorably in the media.
Lexeo Therapeutics' return on equity of -49.58% beat JATT Acquisition's return on equity.
JATT Acquisition has lower revenue, but higher earnings than Lexeo Therapeutics.
Lexeo Therapeutics received 6 more outperform votes than JATT Acquisition when rated by MarketBeat users.
Lexeo Therapeutics currently has a consensus price target of $20.80, indicating a potential upside of 25.08%. Given JATT Acquisition's higher possible upside, analysts plainly believe Lexeo Therapeutics is more favorable than JATT Acquisition.
60.7% of Lexeo Therapeutics shares are owned by institutional investors. Comparatively, 48.0% of JATT Acquisition shares are owned by institutional investors. 4.5% of Lexeo Therapeutics shares are owned by company insiders. Comparatively, 20.0% of JATT Acquisition shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
Summary
Lexeo Therapeutics beats JATT Acquisition on 7 of the 11 factors compared between the two stocks.
Get JATT Acquisition News Delivered to You Automatically
Sign up to receive the latest news and ratings for JATT and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding JATT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
JATT Acquisition Competitors List
Related Companies and Tools
